What is New on Thyroid Cancer Biomarkers
Thyroid cancer harbours in about 5% of thyroid nodules. The majority of them are well-differentiated cancers originating from the follicular epithelium, and are subdivided into papillary and follicular carcinomas. Undifferentiated carcinomas and medullary thyroid carcinomas arising from C cells are...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2008-01-01
|
Series: | Biomarker Insights |
Online Access: | https://doi.org/10.4137/BMI.S669 |
id |
doaj-8870970feba2421c8f4b524ab15f2088 |
---|---|
record_format |
Article |
spelling |
doaj-8870970feba2421c8f4b524ab15f20882020-11-25T03:43:31ZengSAGE PublishingBiomarker Insights1177-27192008-01-01310.4137/BMI.S669What is New on Thyroid Cancer BiomarkersRosaria M. Ruggeri0Alfredo Campennì1Sergio Baldari2Francesco Trimarchi3Maria Trovato4Sezione di Endocrinologia, Dipartimento Clinico-Sperimentale di Medicina e Farmacologia.U.O. di Medicina Nucleare, Dipartimento di Scienze Radiologiche.U.O. di Medicina Nucleare, Dipartimento di Scienze Radiologiche.Sezione di Endocrinologia, Dipartimento Clinico-Sperimentale di Medicina e Farmacologia.Dipartimento di Patologia Umana, University of Messina, Policlinico Universitario, “G. Martino”, Messina, Italy.Thyroid cancer harbours in about 5% of thyroid nodules. The majority of them are well-differentiated cancers originating from the follicular epithelium, and are subdivided into papillary and follicular carcinomas. Undifferentiated carcinomas and medullary thyroid carcinomas arising from C cells are less common. Although most thyroid nodules are benign, distinguishing thyroid cancer from benign lesions is crucial for an appropriate treatment and follow-up. The fine needle aspiration cytology (FNAC) allows the diagnosis of nature of thyroid nodules in the majority of cases. However, FNAC has some limitations, particularly in the presence of follicular lesions which can appear dubious in rare instances even at histology. In an effort to improve diagnostic accuracy and offer new prognostic criteria, several immunohistochemical and molecular markers have been proposed. However, most of them have to be validated on large series before being used in routine practice.https://doi.org/10.4137/BMI.S669 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Rosaria M. Ruggeri Alfredo Campennì Sergio Baldari Francesco Trimarchi Maria Trovato |
spellingShingle |
Rosaria M. Ruggeri Alfredo Campennì Sergio Baldari Francesco Trimarchi Maria Trovato What is New on Thyroid Cancer Biomarkers Biomarker Insights |
author_facet |
Rosaria M. Ruggeri Alfredo Campennì Sergio Baldari Francesco Trimarchi Maria Trovato |
author_sort |
Rosaria M. Ruggeri |
title |
What is New on Thyroid Cancer Biomarkers |
title_short |
What is New on Thyroid Cancer Biomarkers |
title_full |
What is New on Thyroid Cancer Biomarkers |
title_fullStr |
What is New on Thyroid Cancer Biomarkers |
title_full_unstemmed |
What is New on Thyroid Cancer Biomarkers |
title_sort |
what is new on thyroid cancer biomarkers |
publisher |
SAGE Publishing |
series |
Biomarker Insights |
issn |
1177-2719 |
publishDate |
2008-01-01 |
description |
Thyroid cancer harbours in about 5% of thyroid nodules. The majority of them are well-differentiated cancers originating from the follicular epithelium, and are subdivided into papillary and follicular carcinomas. Undifferentiated carcinomas and medullary thyroid carcinomas arising from C cells are less common. Although most thyroid nodules are benign, distinguishing thyroid cancer from benign lesions is crucial for an appropriate treatment and follow-up. The fine needle aspiration cytology (FNAC) allows the diagnosis of nature of thyroid nodules in the majority of cases. However, FNAC has some limitations, particularly in the presence of follicular lesions which can appear dubious in rare instances even at histology. In an effort to improve diagnostic accuracy and offer new prognostic criteria, several immunohistochemical and molecular markers have been proposed. However, most of them have to be validated on large series before being used in routine practice. |
url |
https://doi.org/10.4137/BMI.S669 |
work_keys_str_mv |
AT rosariamruggeri whatisnewonthyroidcancerbiomarkers AT alfredocampenni whatisnewonthyroidcancerbiomarkers AT sergiobaldari whatisnewonthyroidcancerbiomarkers AT francescotrimarchi whatisnewonthyroidcancerbiomarkers AT mariatrovato whatisnewonthyroidcancerbiomarkers |
_version_ |
1724519318392143872 |